Skip to main content
Sartorius Stedim Biotech logo

Sartorius Stedim Biotech — Investor Relations & Filings

Ticker · DIM ISIN · FR0013154002 LEI · 52990006IVXY7GCSSR39 PA Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2025-06-02 Declaration of Voting R…
Country FR France
Listing PA DIM

About Sartorius Stedim Biotech

https://www.sartorius.com/en

Sartorius Stedim Biotech is a leading international provider of equipment and services for the biopharmaceutical industry. The company offers integrated solutions that support the entire lifecycle of drug development and manufacturing, from research and development to quality assurance and commercial production. Its comprehensive portfolio includes technologies for filtration, fluid management, fermentation, cell culture, and purification. Key products encompass bioreactors, single-use systems, process filtration equipment, cell culture media, and data analytics software. Sartorius Stedim Biotech enables its customers to develop and manufacture biotech medications, including cell and gene therapies, more efficiently and safely, helping to accelerate the translation of scientific discoveries into patient care.

Recent filings

Filing Released Lang Actions
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose in the title: 'DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL'. It provides a table detailing the total number of shares, theoretical voting rights, and net voting rights as of a specific date (May 31, 2025), referencing French commercial code and AMF regulations. This content directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or, in this context, the official declaration of the total voting capital structure.
2025-06-02 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL' (Declaration relative to the number of shares and voting rights comprising the share capital) and cites French regulations (Article L 233-8-II du Code de commerce and article 223-6 du règlement général de l'AMF). It provides a table detailing the total number of shares, theoretical voting rights, and net voting rights as of a specific date (May 31, 2025). This type of mandatory disclosure regarding the total voting power and share capital structure is a specific regulatory filing requirement, often related to capital structure updates or general corporate governance disclosures, but it does not fit perfectly into the primary categories like 10-K, ER, or DIV. Given the options, it is a specific regulatory disclosure concerning capital structure and voting rights. Since there is no specific code for 'Share Capital/Voting Rights Declaration,' and it is a formal regulatory filing providing key structural data, it is best classified as a general Regulatory Filing (RNS) or potentially related to Capital/Financing Update (CAP) if the change was significant, but RNS is the safest fallback for specific, non-standard regulatory reports. However, looking closely at the definitions, it is a declaration about the capital structure itself, which is a fundamental corporate action/status update. Since it is a formal declaration required by law, and not a general announcement of a report (RPA), RNS is the most appropriate general regulatory category.
2025-06-02 French
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL" and explicitly references French regulatory articles (Article L 233-8-II of the Code of commerce and article 223-6 of the general regulations of the AMF). It provides a table detailing the total number of shares and voting rights as of May 31, 2025. This content directly relates to official disclosures regarding the company's capital structure and voting rights, which falls under the scope of Declaration of Voting Results & Voting Rights Announcements (DVA). Although it is a regulatory filing, DVA is the most specific category for this type of capital/voting rights declaration.
2025-06-02 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose in the title: 'DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL'. It provides a table detailing the total number of shares, theoretical voting rights, and net voting rights as of a specific date (April 30, 2025), referencing French commercial code and AMF regulations. This content directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or, in this context, the official declaration of the total voting capital structure.
2025-05-05 English
Sartorius Stedim Biotech SA: DECLARATION RELATIVE AU NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is titled 'DECLARATION RELATIVE AU NOMBRE D'ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL' (Declaration relative to the number of shares and voting rights comprising the share capital) and references French commercial code (Article L 233-8-II du Code de commerce) and AMF regulations. It provides a table detailing the total number of shares, theoretical voting rights, and net voting rights as of a specific date (April 30, 2025). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing, often related to capital structure updates or required periodic reporting on ownership structure. It is not a full Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). Given the specific nature of reporting share capital and voting rights, it aligns best with a specialized regulatory disclosure. Since there is no specific code for 'Share Capital/Voting Rights Declaration,' and it is a formal regulatory filing, it falls under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure that doesn't fit the other specific financial or corporate action codes. The document length is short (1339 chars), but it is the report itself, not an announcement of a report.
2025-05-05 French
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Regulatory Filings Classification · 1% confidence The document is titled "DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL" and explicitly references French regulatory articles (L 233-8-II of the Code of commerce and article 223-6 of the general regulations of the AMF). It provides a table detailing the total number of shares and voting rights as of April 30, 2025. This content directly relates to official disclosures regarding the company's capital structure and voting rights, which falls under the scope of regulatory announcements. While it is a specific declaration, it is not a general AGM result (DVA) or a general regulatory filing (RNS). The closest specific category that deals with capital structure changes or official voting rights declarations, especially when not tied to a specific meeting result, is often captured by general regulatory disclosures. However, given the specific nature of reporting total shares and voting rights, and comparing it against the provided definitions, it is a specific regulatory disclosure. Since there isn't a perfect fit for 'Declaration of Total Shares/Voting Rights', I must evaluate the options. It is not an AGM result (DVA), nor a general share issue (SHA). It is a mandatory regulatory disclosure. In many classification schemes, such mandatory periodic capital structure disclosures are grouped under general regulatory filings (RNS) or sometimes under specific capital/share announcements. Given the options, and recognizing this is a mandatory disclosure about the capital base, it fits best as a general Regulatory Filing (RNS) as it is a specific regulatory news item transmitted via EQS, or potentially DVA if interpreted broadly as a voting rights declaration, but DVA is defined as 'Official results from shareholder votes'. Therefore, RNS is the most appropriate fallback for a specific, non-financial, non-management regulatory notice.
2025-05-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.